Conference Correspondent

Vaccination against human papillomavirus (HPV) can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers. Unfortunately, vaccination rates, as well as public knowledge regarding the link between HPV and these cancers, are lagging, according to research presented during the 2023 American Association for Cancer Research Annual Meeting. Read More ›

Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–­small-cell lung cancer (NSCLC) with KRAS p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial. Read More ›

The number of cancer survivors continues to increase in the United States, which can be attributed to a growing and aging population, as well as recent advances in diagnosis and treatment. Read More ›

The use of a polygenic score (PGS) based on noncancer genetic variations in prostate-specific antigen (PSA) values helped to refine PSA screening in a large group of men without prostate cancer at baseline. Read More ›

Selpercatinib (Retevmo) demonstrated antitumor activity in RET fusion–positive tumors other than lung cancer and thyroid cancer, according to interim results from the phase 1/2 LIBRETTO-001 clinical trial. Results from the trial were presented by Vivek Subbiah, MD, Medical Director, Clinical Center for Targeted Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, at the 2021 virtual American Association for Cancer Research annual meeting. Read More ›

The addition of the PI3K inhibitor copanlisib (Aliopa) to rituximab (Rituxan) reduced the risk for disease progression or death by 48% compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (NHL) in the phase 3 CHRONOS-3 clinical trial. The results of this study were presented at the 2021 virtual American Association for Cancer Research (AACR) annual meeting and published simultaneously in The Lancet Oncology. Read More ›

Treatment with tebentafusp (IMCgp100), a novel bispecific T-cell receptor (TCR) fusion protein, extended survival in patients with metastatic uveal melanoma, according to the results from a recent phase 3 trial. Read More ›

Pragmatic setting administration of the all-oral combination of pomalidomide plus cyclophosphamide/dexamethasone (POMCIDEX) is a manageable, effective treatment option for patients with relapsed/refractory multiple myeloma. Read More ›

Based on early results of a dose-escalation study, teclistamab demonstrated an overall response rate of 67% at the highest dose, as well as reasonable tolerability with low incidence of high-grade cytokine release syndrome in patients with advanced relapsed/refractory multiple myeloma. Read More ›

Isatuximab plus carfilzomib/dexamethasone (IKEMA study) shows promising efficacy and tolerable safety in prolonging progression-free survival compared with carfilzomib/dexamethasone alone in the treatment of patients with RRMM. Read More ›